Evaluation of Functional Independence and Pain in Covid-19 Patients with Mild Neurological Impairments during the Hospital Stay

Main Article Content

Vijay Krishna Kumar
Archana Puttaiah
Girija Murugan
Shruthi Raju

Abstract

Background: Novel COVID 19 is a infectious disease caused by a recently discovered corona virus. It is characterized as an acute respiratory syndrome followed by neurological diseases like acute necrotizing encephalopathy/disseminated encephalomyelitis, Guillain – barre syndrome, stroke inflammatory neuropathy. Common clinical symptoms include headache, insomnia, dizziness, delirium, myopathy, ataxia, seizures, complete/partial anosmia, ageusia, hypoxia, muscle and nerve pain and peripheral nervous system manifestation. The purpose of this survey was to evaluate the functional independence and pain in Covid-19 patients with mild neurological impairments during the hospital stay.


Method: 85 covid–19 diagnosed patients with mild neurological impairments such as non-specific headache, anosmia, aguesia, myalgia, fatigue etc. of age group 25 to 60 years admitted in hospital were recruited. Patient function is assessed using the FIM instrument at the time of admission and at the time of discharge. The severity of the patient’s pain and the impact of this pain on the patient’s daily functioning was evaluated using the brief pain inventory scale. Patients with comorbidity diseases like surgery and cancer, infants, children, ventilated ICU patients were excluded from the study.


Results: The study found that among  the 85 respondent participants majority of  53(62.4%) had severe pain and  82 of them(96.5%) had high pain interference. According to the interpretation the total FIM score shows a significant improvement from admission to discharge with the p-value of 0.000.


Conclusion: The study concluded that there was a significant difference on functional independence and pain in Covid-19 patients with mild neurological impairments during the hospital stay.

Article Details

How to Cite
Vijay Krishna Kumar, Archana Puttaiah, Girija Murugan, & Shruthi Raju. (2021). Evaluation of Functional Independence and Pain in Covid-19 Patients with Mild Neurological Impairments during the Hospital Stay. International Journal of Medical Science and Clinical Research Studies, 1(8), 247–253. https://doi.org/10.47191/ijmscrs/v1-i8-05
Section
Articles

References

I. Velavan TP, Meyer CG. La epidemia de COVID-19.Trop Med Int Health. 2020; 25(3).

II. Cron RQ, Chatham WW.The rheumatologist’s role in COVID-19.

III. Gupta R, Pal SK, Pandey G. A comprehensive analysis of COVID-19 outbreak situation in India. MedRxiv. 2020 Jan 1.

IV. Barker-Davies RM, O'Sullivan O, Senaratne KP, Baker P, Cranley M, Dharm-Datta S, Ellis H, Goodall D, Gough M, Lewis S, Norman J. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. British journal of sports medicine. 2020 Aug 1; 54(16):949-59.

V. Velavan TP, Meyer CG. The COVID‐19 epidemic. Tropical medicine & international health. 2020 Mar; 25(3):278.

VI. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH, Wong JY, Xing X. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England journal of medicine. 2020 Jan 29.

VII. Antonelli A, Elia G, Ferrari SM, Foddis R, De Marco S, Cristaudo A, Fallahi P. The COVID-19, epidemiology, clinic and prevention. Current genomics. 2020 Apr; 21(3):157.

VIII. Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, Liu JP. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chinese journal of integrative medicine. 2020 Apr; 26(4):243-50.

IX. World Health Organization. World Health Organization coronavirus disease (COVID-19) dashboard. World Health Organization. 2021.

X. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. cell. 2020 Apr 16; 181(2):271-80.

XI. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral research. 2020 Apr 1; 176:104742.

XII. Qi J, Zhou Y, Hua J, Zhang L, Bian J, Liu B, Zhao Z, Jin S. The scRNA-seq expression profiling of the receptor ACE2 and the cellular protease TMPRSS2 reveals human organs susceptible to SARS-CoV-2 infection. International Journal of Environmental Research and Public Health. 2021 Jan; 18(1):284.

XIII. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, Bucci E, Piacentini M, Ippolito G, Melino G. COVID-19 infection: the perspectives on immune responses.

XIV. Snoeck M, Van Engelen BG, Küsters B, Lammens M, Meijer R, Molenaar JP, Raaphorst J, Verschuuren‐Bemelmans CC, Straathof CS, Sie LT, de Coo IF. RYR 1‐related myopathies: a wide spectrum of phenotypes throughout life. European journal of neurology. 2015 Jul;22(7):1094-112.

XV. Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infectious diseases of poverty. 2020 Dec; 9(1):1-7.

XVI. Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S, Braun F. Multiorgan and renal tropism of SARS-CoV-2. New England Journal of Medicine. 2020 Aug 6; 383(6):590-2.

XVII. Garg RK. Spectrum of neurological manifestations in Covid-19: a review. Neurology India. 2020 May 1; 68(3):560.